Vanguard Group’s Akoya BioSciences AKYA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-1,194,127
| Closed | -$1.55M | – | 4348 |
|
|
2025
Q2 | $1.55M | Sell |
1,194,127
-194,073
| -14% | -$233K | ﹤0.01% | 3617 |
|
|
2025
Q1 | $1.93M | Sell |
1,388,200
-18,862
| -1% | -$41.3K | ﹤0.01% | 3502 |
|
|
2024
Q4 | $3.22M | Sell |
1,407,062
-77,911
| -5% | -$206K | ﹤0.01% | 3424 |
|
|
2024
Q3 | $4.04M | Buy |
1,484,973
+21,120
| +1% | +$51.6K | ﹤0.01% | 3349 |
|
|
2024
Q2 | $3.43M | Buy |
1,463,853
+9,565
| +0.7% | +$30.5K | ﹤0.01% | 3396 |
|
|
2024
Q1 | $6.82M | Buy |
1,454,288
+46,131
| +3% | +$240K | ﹤0.01% | 3160 |
|
|
2023
Q4 | $6.87M | Buy |
1,408,157
+57,762
| +4% | +$240K | ﹤0.01% | 3149 |
|
|
2023
Q3 | $6.28M | Buy |
1,350,395
+41,265
| +3% | +$237K | ﹤0.01% | 3156 |
|
|
2023
Q2 | $9.67M | Buy |
1,309,130
+321,357
| +33% | +$2.15M | ﹤0.01% | 2963 |
|
|
2023
Q1 | $8.08M | Buy |
987,773
+40,146
| +4% | +$419K | ﹤0.01% | 3058 |
|
|
2022
Q4 | $9.07M | Buy |
947,627
+25,587
| +3% | +$315K | ﹤0.01% | 2994 |
|
|
2022
Q3 | $10.8M | Buy |
922,040
+141,017
| +18% | +$1.86M | ﹤0.01% | 2922 |
|
|
2022
Q2 | $10M | Buy |
781,023
+80,200
| +11% | +$831K | ﹤0.01% | 2990 |
|
|
2022
Q1 | $7.7M | Buy |
700,823
+25,845
| +4% | +$300K | ﹤0.01% | 3291 |
|
|
2021
Q4 | $10.3M | Buy |
674,978
+327,323
| +94% | +$4.28M | ﹤0.01% | 3182 |
|
|
2021
Q3 | $4.85M | Buy |
347,655
+2,720
| +0.8% | +$45.5K | ﹤0.01% | 3680 |
|
|
2021
Q2 | $6.67M | Buy |
+344,935
| New | +$7.12M | ﹤0.01% | 3424 |
|
Vanguard Group's AKYA Position: Q3 2025 in Review
Vanguard Group sold out of Akoya BioSciences (AKYA) in Q3 2025, closing a stake of 1,194,127 shares — an estimated $1.55M sold.
Vanguard Group first reported a position in AKYA in Q2 2021 and held it in 17 quarters. The position peaked at $10.8M in Q3 2022. 0 funds tracked by Wall St. Rank hold AKYA as of Q3 2025.
- Vanguard Group reported no remaining Akoya BioSciences position as of Q3 2025 after selling out during the quarter.
- Vanguard Group sold 1,194,127 Akoya BioSciences shares in Q3 2025, an estimated $1.55M.
- Vanguard Group first reported a position in Akoya BioSciences in Q2 2021 and held it in 17 quarters.
- Vanguard Group's Akoya BioSciences position peaked at $10.8M in Q3 2022.
- 0 funds tracked by Wall St. Rank held Akoya BioSciences as of Q3 2025.
Based on Vanguard Group's 13F filing for Q3 2025, filed 7 Nov 2025.